2023-2024 Regular Session • US Congress Legislature
SB5206: United States Pharmaceutical Supply Chain Review Act
Legislative Summary
A bill to require a report on foreign investment in the pharmaceutical industry of the United States.
Demographic Impact
Overall analysis of equity impact
80% Positive
Medium ConfidenceView detailed demographic breakdown ↓Unlock Full Demographic Insights
Go beyond the overall score.
Gain a deeper understanding of this bill's potential impact across diverse communities, including detailed breakdowns by category and subgroup. Access to this granular analysis helps ensure equitable outcomes.
Enable full analysis features for your organization.
Contact Sales to Learn MoreOr email us directly at sales@legiequity.us.
Bill History
9/25/2024
Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
Senate
Status Information
Current Status
Introduced(9/25/2024)
Chamber
Senate
Committee
Banking, Housing, And Urban Affairs(Senate)
